Table 2.

Patient characteristics

Characteristics	Overall n=50	Patients with negative LNs n=35 (70%)	Patients with positive LNs n=15 (30%)
Age, years (median) IQR	66.5 61–72	66 60–71	72 64–74
Total PSA, ng/mL (median) IQR	9.84 5.89–14.53	9.61 5.09–12.54	10.27 7.18–24.34
No of LN removed (median) IQR	16.5 13–21	16 12–21	18 15–21
No of SLN removed (median) IQR	9 6–12	8 5–12	11 7–13
No of positive LN (median) IQR	–	–	2 1–2
Tumor stage (%)
T1c	28 (56)	24 (68.57)	4 (26.67)
T2a	2 (4)	1 (2.86)	1 (6.67)
T2b	6 (12)	4 (11.43)	2 (13.33)
T2c	13 (26)	5 (14.29)	8 (53.33)
T3	1 (2)	1 (2.86)	0 (0)
Biopsy Gleason score (%)
6 (3+3)	9 (18)	9 (25.71)	0 (0)
7 (3+4)	24 (48)	19 (54.29)	5 (33.33)
7 (4+3)	9 (18)	7 (20)	2 (13.33)
≥8	8 (16)	0 (0)	8 (53.33)
Postoperative Gleason score (%)
6 (3+3)	1 (2)	1 (2.86)	0 (0)
7 (3+4)	26 (52)	24 (68.57)	2 (13.33)
7 (4+3)	13 (26)	8 (22.86)	5 (33.33)
≥8	10 (20)	2 (5.71)	8 (53.33)
Pathologic stage (%)
pT2	27 (54)	26 (74.29)	1 (6.67)
pT3a	12 (24)	6 (17.14)	6 (40)
pT3b	10 (20)	2 (5.71)	8 (53.33)
pT4	1 (2)	1 (2.86)	0 (0)

Abbreviations: LN, lymph node; PSA, prostate specific antigen.